Peer Review History
| Original SubmissionNovember 8, 2020 |
|---|
|
PONE-D-20-35143 Generation and characterization of a Meflin-CreERT2 transgenic line for lineage tracing in white adipose tissue PLOS ONE Dear Dr. Tobe, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Feb 12 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Nobuyuki Takahashi, Ph.D. Academic Editor PLOS ONE Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions. Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: N/A ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors generated the tamoxifen-induced transgenic mice with Meflin, which w as a major maker of the mesenchymal stem cell. Meflin was expressed on the crown -like structure (CLS) in the adipose tissue of high fat diet-fed mice. The Mefli n-expressing lineage cells were differentiated to the beige adipocytes by the co ld exposure. 1. To what degree did Mefrin mRNA and protein expression levels increase in the adipose tissue of Meflin transgenic mice compared to those of control mice? 2. Do other mesenchymal stem cell (MSC) markers, such as CD90, CD105 and Sca-1 e levate in the adipose tissues of high fat diet-fed mice or after the cold exposu re? 3. Please show the ratio of Meflin-positive cells in the adipose tissue of norma l chow-fed mice in Figure 3F. 4. It is recommended that the authors measure the expression levels of Meflin in UCP-1 positive cells of the adipose tissue after cold stimulation. 5. There was no description of Figure 4B’ in Result section. 6. The phenotypes of high-fat diet-fed Meflin transgenic mice, such as inflammat ion and insulin sensitivity, are not mentioned in the text. Please specify those phenotypes. Reviewer #2: In this article, the authors generated Meflin-CreERT2 mice, and they performed lineage tracing using this mouse model. They showed that Meflin-expressing lineage cells exists in various tissues. In WAT, Meflin-expressing lineage cells were present in stroma and differentiated into mature adipocytes under HFD feeding condition. They also showed that Meflin-expressing lineage cells can differentiate into beige adipocytes under cold temperature. This article contains interesting findings. Please respond to the concerns listed below. 1. L120, “2 min at 4 ℃” should be “2 min at 94 ℃”. 2. The authors should determine the copy number of inserted DNA in mice used this study (Fig.2 ~) by Southern blotting. 3. Fig.2. tdTomato-derived fluorescence in some images is very weak and blurry, and it is very difficult to judge which cells are tdTomato positive cells. Especially, the fluorescence from brown adipose tissue, liver, intestine, testis, and kidney looks very weak, and it is difficult to exclude the possibility that these fluorescences are autofluorescence. The authors should show clearer images and clarify that these fluorescencea are not from autofluorescence. 4. In Fig.2, which white adipose tissue depot was used? gWAT? iWAT? 5. Fig.3. Similar to the case of Fig.2, tdTomato-derived fluorescence in some images is very weak and blurry (Fig.3A and 3B). 6. Fig.3. From the images of 3C, 3D, it looks like a very limited number of adipocytes are tdTomato positive (Meflin-expressing lineage cells). However, in Fig 3E and 3F, approximately half of the adipocytes are GFP positive, suggesting that these cells are Meflin-expressing lineage cells. The authors should explain this discrepancy. 7. L238, the author mentioned “Meflin-expressing lineage cells differentiate into mature adipocytes that constitute CLS”. However, they also showed that tdTomato-expressing cells in CLS also express F4/80, suggesting that Meflin-expressing lineage cells in CLS are macrophages. Therefore, the authors should clarify whether Meflin-expressing lineage cells in CLS are adipocytes or macrophages. 8. L261, “Fig 3C” should be “Fig 3D”. 9. Fig.4B. Similar to the case of Fig.2, tdTomato-derived fluorescence is too weak and blurry to judge whether these cells are tdTomato positive. 10. Fig.4. There is only one beige adipocyte in these images, and it is difficult to judge whether all beige adipocytes are derived from Meflin-expressing lineage cells. Thus, the authors should show images containing many beige adipocytes at a low magnification. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Generation and characterization of a Meflin-CreERT2 transgenic line for lineage tracing in white adipose tissue PONE-D-20-35143R1 Dear Dr. Tobe, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Nobuyuki Takahashi, Ph.D. Academic Editor PLOS ONE Additional Editor Comments: Authors addressed all of the Reviewers' comments in this revised manuscript. |
| Formally Accepted |
|
PONE-D-20-35143R1 Generation and characterization of a Meflin-CreERT2 transgenic line for lineage tracing in white adipose tissue Dear Dr. Tobe: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Nobuyuki Takahashi Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .